Viracta Therapeutics

$8.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-0.37%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

You can buy or sell VIRX and other stocks, options, and ETFs commission-free!

About VIRX

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas.

CEO
Ivor Royston
Employees
8
Headquarters
Cardiff, California
Founded
1998
Market Cap
294.89M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
238.21K
High Today
$8.21
Low Today
$7.86
Open Price
$7.93
Volume
157.00K
52 Week High
$24.80
52 Week Low
$3.92

VIRX Earnings

Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 5

You May Also Like

BMRC
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure